MacroGenics, Inc. (MGNX) Dividend History

Company News

• Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

  Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of MacroGenics, Apellis Pharmaceuticals, Teradata, and Maplebear. The investigations are related to alleged false and misleading statements made by the companies.

  GlobeNewswire Inc.

  Featured Companies: APLS CART TDC
• Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential

  The global immunotoxins market is projected to grow at a CAGR of 8.11% from 2024 to 2034, driven by the rising prevalence of malignancies, increased R&D, and the approval of new immunotoxin therapies. Diphtheria toxin-based immunotoxins lead revenue, while Pseudomonas exotoxins show rapid growth potential.

  GlobeNewswire Inc.

  Featured Companies: ABBV AMGN BMY IOVA MRK ZYME
• Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

  Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of MacroGenics, Apellis Pharmaceuticals, Teradata, and Maplebear. The investigations are related to alleged false and misleading statements made by the companies.

  GlobeNewswire Inc.

  Featured Companies: APLS CART TDC
• Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight

  The market for B7-H3 inhibitors is expected to grow significantly due to rising investment from leading pharma companies, increasing cancer diagnoses, and a growing number of B7-H3 inhibitors in clinical trials.

  GlobeNewswire Inc.

  Featured Companies: MRK
• Hagens Berman Alerts MacroGenics (MGNX) Investors to Today’s Lead Plaintiff Deadline in Securities Class Action

  MacroGenics, a pharmaceutical company, is facing a securities class action lawsuit alleging that it misled investors about the safety and efficacy of its experimental cancer drug, vobra duo. The lawsuit centers on the company's statements regarding data from a Phase 2 clinical trial, where it initially painted a positive picture of the drug's performance, but later revealed safety concerns and patient deaths, causing a significant drop in the stock price.

  GlobeNewswire Inc.